North America Antibody Drug Conjugates Market Size & Outlook
North America antibody drug conjugates market, 2018-2030 (US$M)
Related Markets
North America antibody drug conjugates market highlights
- The North America antibody drug conjugates market generated a revenue of USD 3,289.5 million in 2021.
- The market is expected to grow at a CAGR of 13.8% from 2022 to 2030.
- In terms of segment, breast cancer was the largest revenue generating application in 2021.
- Other Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2022 to 2030.
North America data book summary
| Market revenue in 2021 | USD 3,289.5 million |
| Market revenue in 2030 | USD 10,565.1 million |
| Growth rate | 13.8% (CAGR from 2021 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Other Cancer |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, North America region accounted for 56.6% of the global antibody drug conjugates market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.
Breast cancer was the largest segment with a revenue share of 52.34% in 2021. Horizon Databook has segmented the North America antibody drug conjugates market based on blood cancer, breast cancer, urothelial cancer & bladder cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
North America is expected to witness significant growth over the forecast period, owing to factors such as increased awareness about current treatment therapies, favorable reimbursement policies, significant R&D expenditure, and improved patient affordability. Some of the key market players operating in this region are Seagen, Inc.
F. Hoffmann La-Roche Ltd.; Gilead Sciences Inc.; and Pfizer Inc. The region has an excellent healthcare infrastructure. In countries such as Canada, the healthcare system is publicly funded, further increasing people’s access to treatment options for conditions such as cancer.
Co-payment options are also provided by some drug companies operating in the region for patients under certain conditions, to help reduce overall out-ofpocket expenditure. Furthermore, the North American region has one of the highest prevalence of cancers in the world, which includes breast cancer, leukemia, and lymphoma, propelling the demand for ADCs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America antibody drug conjugates market size, by country, 2018-2030 (US$M)
North America Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
